Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.97 HKD | -0.10% | -2.25% | -35.68% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-35.68% | 651M | - | ||
-2.32% | 90.45B | A- | ||
+3.68% | 41.45B | A- | ||
-10.90% | 33.57B | B- | ||
+58.05% | 25.73B | A | ||
-19.56% | 14.73B | C | ||
-9.06% | 12.82B | B- | ||
-11.34% | 11.7B | D+ | ||
-43.53% | 11.44B | B | ||
+3.75% | 8.79B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6955 Stock
- Ratings Shandong Boan Biotechnology Co., Ltd.